COPYRIGHT © BY THE JOURNAL OF BONE AND JOINT SURGERY, INCORPORATED DIGIOVANNI ET AL

Recombinant Human Platelet-Derived Growth Factor-BB and Beta-Tricalcium Phosphate (RHPDGF-BB/ $\beta$ -TCP): An Alternative to ... http://dx.doi.org/10.2106/JBJS.K.01422

Page 1 of 1

## **TABLE E-1 Study Entry Criteria**

## Inclusion Criteria

- 1. The patient signed the institutional review board-approved informed consent form.
- 2. A bone defect in the hindfoot or ankle required arthrodesis with use of open surgical technique with supplemental bone graft, requiring one of the following procedures: ankle joint arthrodesis (tibiotalar arthrodesis), subtalar arthrodesis, calcaneocuboid arthrodesis, talonavicular arthrodesis, triple arthrodesis (subtalar, talonavicular, and calcaneocuboid joints), and double arthrodesis (e.g., talonavicular and calcaneocuboid joints).
- 3. The arthrodesis site was able to be rigidly stabilized with no more than three screws across the arthrodesis site. Supplemental screws external to the arthrodesis site(s) were also allowed.
- 4. The patient was independent, could walk, and could comply with all postoperative assessments.
- 5. The patient was at least eighteen years of age and was considered to be skeletally mature.

## Exclusion Criteria

- 1. The patient had undergone previous surgery of the proposed arthrodesis site.
- 2. The arthrodesis site required plate fixation, more than three screws, or more than 9 cc of graft material.
- 3. There was radiographic evidence of bone cysts, segmental defects, or growth plate fracture around the arthrodesis site that may negatively impact osseous fusion.
- 4. There were untreated malignant neoplasm(s) at the surgical site, or the patient was currently undergoing radiotherapy or chemotherapy.
- 5. The patient had a preexisting sensory impairment (e.g., diabetes with baseline sensory impairment) that limited the ability to perform objective functional measurements. Patients with diabetes who were not sensitive to the 5.07 monofilament (Semmes-Weinstein) were excluded.
- 6. The patient had a metabolic disorder such as renal osteodystrophy or hypercalcemia known to adversely affect the skeleton, other than primary osteoporosis or diabetes.
- 7. The patient chronically used medications known to affect the skeleton (e.g., glucocorticoid usage >10 mg per day). Nonsteroidal anti-inflammatory drug (NSAID) use was excluded during the first six weeks postoperatively.
- 8. The patient had a neuromuscular or musculoskeletal deficiency that limited the ability to perform objective functional measurements.
- 9. The patient was physically or mentally compromised (e.g., was currently being managed for a psychiatric disorder, senile dementia, Alzheimer disease, and so forth) to the extent that the investigator judged the patient to be unable or unlikely to remain compliant.
- 10. The patient had an allergy to yeast-derived products.
- 11. The patient had undergone an investigational therapy or an approved therapy for investigational use within thirty days of surgery or during the follow-up phase of this study.
- 12. The patient was a prisoner, was known to be or was suspected of being transient, or had a history of drug or alcohol abuse within the twelve months prior to screening for study entry.
- 13. The patient was pregnant or was intending to become pregnant during the study period. A urine pregnancy test was administered within twenty-one days of the surgical visit to any female patient unless she was postmenopausal, had been sterilized, or was practicing a medically accepted method of contraception.
- 14. The patient was deemed morbidly obese (body mass index [BMI], >45 kg/m<sup>2</sup>).